About This Site

What Medicine Tirzepatide is

Medicine Tirzepatide is a plain-language reader of the peer-reviewed research literature on tirzepatide — the dual GIP/GLP-1 receptor agonist studied across the SURPASS and SURMOUNT clinical programs. Nothing is sold, supplied, or dispensed here; no clinician is on staff; and no line on the site is medical advice, a prescription, or a treatment recommendation.

The word "medicine" in the domain name marks the register of the project: a site positioned where the published medical literature meets general readability. It is a designation — the vantage the publisher takes toward the clinical literature — not a claim about clinical services offered here. There are no services offered here.

What we publish

Every page on this site is a summary or digest of findings from the published, peer-reviewed literature. The primary sources are the SURPASS and SURMOUNT phase 3 trial programs, mechanistic studies published in JCI Insight, Cell Metabolism, Frontiers in Endocrinology, and CPT Pharmacometrics, and the FDA prescribing record for tirzepatide.

Every quantitative claim — a dose, a percentage, an event rate, a trial outcome — maps to a numbered citation in the References section. We do not write claims we cannot source to the published literature. We do not invent findings. If the data are uncertain, we say so.

What we are not

This is no clinic, pharmacy, prescriber, or vendor. It dispenses no medical advice, sells no tirzepatide or any other compound, and offers no consultation, treatment plan, or anything that could constitute clinical care.

Readers looking for clinical guidance on tirzepatide should consult a licensed physician or qualified healthcare provider. This site is a reading resource for people who want to understand what the published research says — not a substitute for professional medical judgment.

For the frequently asked questions, see frequently asked questions. For the full trial reference list, see the tirzepatide clinical trial data page.

Editorial standards

We apply four rules to every page:

1. Every quantitative claim cites a study from the peer-reviewed literature or the FDA prescribing record.
2. Dosing information is presented as documented in trial protocols — third person, study-attributed, never as a personal recommendation.
3. No competitor brand names appear on this site. Generic compound names (tirzepatide, semaglutide, dulaglutide) are used throughout.
4. Adverse event data and safety findings receive the same editorial prominence as efficacy outcomes. This is a digest of the research as it exists — including its limitations, open questions, and documented risks.